University of Minnesota. Driven to Discover.
Within 2 months of admission, 29% of C diff patients died, compared with 14% of the control group.
A 16-study meta-analysis finds about a 50% higher risk tied to anti-reflux drugs.
The drug may cut all-cause mortality in patients with severe C difficile infection.
Two phase 3 trials showed that a human mononoclonal antibody cut recurrence about 40%.
Though a UK C diff spike was thought to be caused by dirty hospital rooms, that theory proved unlikely.
Gross AE, Johannes RS, Gupta V, et al. The effect of a piperacillin/tazobactam shortage on antimicrobial prescribing and Clostridium difficile risk in 88 U.S. medical centers. Clin Infect Dis 2017 (published online Apr 24)
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Become an underwriter»
CIDRAP - Center for Infectious Disease Research and PolicyAcademic Health Center, University of Minnesota, Minneapolis, MN
© 2017 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.